CCRM supports the development & commercialization of regenerative medicines & associated enabling technologies, with a specific focus on cell & gene therapy.
We're pleased to share our 2025 #annualreport: Reimagining The Possible. It was a year defined by resilience, focus & forward momentum. Read about our collab w/ @IonQ_Inc, progress w/ @CCRM_au & Nordic, successes at our #GMP#CDMO & @CATTI_Training & more https://t.co/jfDPHZVleh
📢 The ISSCR is now accepting nominations for the 2027 ISSCR Board of Directors and the Society's annual awards. Nominations are due 16 October. Learn more 👉https://t.co/fGkqgyJYjF
When knowledge is shared across sectors, the rare disease community can find answers faster and close gaps in care and access. Join the 2026 NORD Breakthrough Summit, Oct. 25–27 in Washington, DC, to exchange ideas and build new connections.
ASGCT staff will be there to connect you with patient education resources (including our new coloring book!), and discuss the latest policies affecting rare disease research and individuals.
Learn more ➡️ https://t.co/6JU0Jm2gJs
#NORDSummit #RareDisease
Last chance—GEN's State of Biotech is tomorrow.
Maraganore. Orkin. Google Cloud's Shweta Maniar. The Biotech Hangout hosts. And John Sterling's exit interview after four decades as GEN's Editor in Chief.
Free registration: https://t.co/j8SYMpSeHX
#biotech#stateofbiotech
📣 Signals is looking for talented bloggers to write about the #regenerativemedicine and #CGT fields. https://t.co/T6iLk6T5tp
If you’re passionate about cutting-edge science and can turn complex ideas into compelling content, we want to hear from you. DM us to learn more #scicomm
A fifth cell and gene therapy product has been approved in the US this year.
Today, the FDA announced approval of an AAV gene therapy developed by ARM member Ultragenyx to treat pediatric patients with Sanfilippo syndrome Type A. 1/2
https://t.co/icwC3ApDJI
How do we make CGTs more accessible to patients globally? In the new episode of our podcast, @bambi_grilley & #StaciArnold explore manufacturing & delivery challenges, regulation, P3s & more. Listen where you stream podcasts or at https://t.co/xFPIF5LSsK. @KristaLambComms
📣 Signals is looking for talented bloggers to write about the #regenerativemedicine and #CGT fields. https://t.co/T6iLk6T5tp
If you’re passionate about cutting-edge science and can turn complex ideas into compelling content, we want to hear from you. DM us to learn more #scicomm
Submit an abstract to the Inaugural Canadian Gene and Cell Therapy Conference by October 1!
Early-career investigators and trainees are invited to submit abstracts highlighting advances across the cell and gene therapy landscape from basic discovery through to clinical implementation. Accepted abstracts will be presented as posters, with selected submissions invited for short oral presentations.
For more information or to submit an abstract, visit https://t.co/yNCw0lc23u.
Thank you to @CIHR_IRSC for supporting this research!
Learn more about how the LUMI-Lab and @UHN researchers (@BowenLi_Lab, @BoWang87, @HAOTIANCUI1, @Yuexulab) are using #AI-enabled robotics to accelerate molecular discovery.
➡️: https://t.co/ADcW75G4I1
The ISSCR recently submitted comments to the #FDA draft guidance for Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.
Read the comments.
https://t.co/uKPxjZi5XH
The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to achieve the intended result. What biotechs really want is speed.
https://t.co/oRbPaBn64r
The 2026 #CellsISee People’s Choice Award voting is now open! "Like" your favourite and the lucky winner will receive $500 at #TMM2026. The #sciart#contest is co-hosted with @StemCellNetwork Vote here: https://t.co/HaWmUnm6Ed Pls RT